

Prolonged QTc appeared in 6 patients (5 with QTc > 500 ms and 1 with JTc > 420 ms due to complete right bundle branch block), which was corrected when part of the medication was suspended as recommended by the cardiologist. Since the implementation of the monitoring protocol, no patient has died due to suspected ventricular arrhythmia associated with prolonged QT interval. Acceptance by the nursing staff has been very satisfactory, because it represents a simple alternative to the complexity of performing 12-lead ECG in these patients.

Nerea Torres González,* Luis Álvarez Acosta,
Alejandro Iriarte Plasencia, Virginia Barreto Cáceres,
Diego Valdivia Miranda, and Julio Salvador Hernández Afonso

Servicio de Cardiología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain

* Corresponding author:

E-mail address: nereatorres@gmail.com (N. Torres González).

Available online 25 June 2020

REFERENCES

1. Ministerio de Sanidad. Manejo clínico del COVID-19: atención hospitalaria. 2020. Available at: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Protocolo_manejo_clinico_ah_COVID-19.pdf. Accessed 3 Apr 2020.
2. Wu C-I, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. *Heart Rhythm*. 2020. <http://dx.doi.org/10.1016/j.hrthm.2020.03.024>.
3. U.S. Food and Drug Administration. Enforcement policy for non-invasive remote monitoring devices used to support patient monitoring during the coronavirus disease 2019 (COVID-19). Public Health Emergency Guidance for Industry and Food and Drug Administration. U.S. Department of Health and Human Services, Food and Drug Administration, and Center for Devices and Radiological Health. 2020. Available at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-non-invasive-remote-monitoring-devices-used-support-patient-monitoring-during>. Accessed 3 Apr 2020.
4. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. *Mayo Clin Proc*. 2020. <http://dx.doi.org/10.1016/j.mayocp.2020.03.024>.

<https://doi.org/10.1016/j.rec.2020.05.027>
1885-5857/

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

The presence of heart disease worsens prognosis in patients with COVID-19



La presencia de cardiopatía agrava el pronóstico de los pacientes con COVID-19

To the Editor,

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gives rise to coronavirus disease 2019 (COVID-19) leading to acute respiratory distress. In Spain, the disease has changed the way hospitals function because they have been overwhelmed by the huge number of admissions and cases of respiratory failure. This situation has required the commitment of all hospital staff, and many cardiologists have been directly involved in the care of these patients. During this task, we have become aware of the clinical impact of cardiovascular risk factors and the prevalence of previous heart disease. We launched a registry to investigate the relevance of these aspects in patients with COVID-19.

Between March 15 and April 11, 2020, we included 522 consecutive patients admitted with a diagnosis of COVID-19, which was confirmed by real-time polymerase chain reaction (rt-PCR) using nasopharyngeal samples. Respiratory failure was defined as a pO₂ of less than 60 mmHg on arterial-blood gas test or O₂ saturation less than 90% without supplemental oxygen. All patients underwent chest X-ray, which was performed by an expert radiologist. Statistical analyses were conducted using parameters at admission.

Categorical variables are expressed as absolute frequency and percentage. Continuous variables are expressed as mean ± standard deviation under the assumption of normal distribution. Groups were compared using the Student *t* test for continuous variables between groups and the chi-square test or Fisher exact test for categorical variables. A logistic regression model was fitted to identify factors associated with hospital mortality. A *P* value of less than .05 was used as a cutoff for statistical significance.

A total of 68 patients (13%) were included in the heart disease group: 42 had ischemic heart disease (30 had a history of myocardial infarction, 32 had undergone percutaneous revascularization, 3 had undergone surgical revascularization, and 4 had compatible symptoms and a positive induced ischemia test), 24 had heart valve disease (all of which were moderate or severe),

and 11 had cardiomyopathy (6 dilated, 2 hypertrophic, and 3 tachycardiomyopathy). Some patients had more than 1 heart disease.

Table 1 shows the comorbidities, clinical characteristics, analytical and radiological parameters, heart rhythm on admission, and clinical evolution of patients with and without heart disease. The patients had a mean age of 68 ± 15 years and 228 (44%) were women. Total mortality was 25% and that of patients with heart disease was 43% (29 patients; *P* < .001): 43% had ischemic heart disease, 37% had heart valve disease, and 64% had cardiomyopathy.

In total, 376 patients underwent an electrocardiogram (ECG), of whom 15 (4%) had a prolonged corrected QT interval, defined as more than 440 milliseconds in men and more than 460 milliseconds in women. Of the 146 without an ECG, 129 (88%) were taking at least 1 drug (lopinavir, ritonavir, hydroxychloroquine, azithromycin) that prolongs the QT interval.

A multivariate analysis was conducted to determine the variables associated with hospital mortality and the combined event of respiratory failure in the course of the disease and mortality). The following variables were included at admission: age, hypertension (HT), diabetes, chronic kidney disease, heart disease, O₂ saturation less than 90%, lymphocytes less than 1000/μL, D-dimer more than 500 μg/L, creatinine more than 1.5 mg/dL, and C-reactive protein more than 10 mg/L. The results are shown in table 2.

This study identified several relevant aspects related to COVID-19 and heart disease: *a*) cardiovascular risk factors (HT, diabetes mellitus, dyslipidemia, smoking) are very common in patients with COVID-19 and, logically, more common in those with heart disease; *b*) patients with heart disease with COVID-19 have a more indolent clinical course, because they very often have respiratory failure and higher mortality; *c*) heart disease is an independent predictor of the combined event of respiratory failure and death; and *d*) an ECG was only performed in 72% of patients despite the use of arrhythmogenic drugs that can prolong the QT interval.

Among the cardiovascular risk factors in our patients, we highlight that the prevalence of hypertension was higher in our series than in other series. An association has previously been found between hypertension and higher mortality in this disease.¹

Table 1
Main characteristics of the patients. comparison between patients with and without heart disease

	Total (n = 522)	With heart disease (n = 68)	Without heart disease (n = 454)	P
Age, y	68 ± 15	75 ± 12	67 ± 15	< .001
Women	228 (44)	17 (25)	211 (47)	.001
Comorbidities				
Hypertension	261 (50)	49 (72)	212 (47)	< .001
Diabetes mellitus	92 (18)	24 (35)	68 (15)	< .001
Chronic kidney disease	37 (7)	8 (12)	29 (6)	.126
Dyslipidemia	190 (37)	45 (66)	145 (32)	< .001
Smoker	141 (27)	33 (51)	108 (24)	< .001
COPD	41 (8)	6 (9)	35 (8)	.793
Clinical parameters				
Temperature > 37.5 °C	328 (72)	42 (76)	286 (72)	.484
SatO ₂ < 90%	94/467 (20)	19/64 (30)	75/403 (19)	.040
Cough	338 (66)	35 (57)	303 (68)	.077
Dyspnea	238 (47)	33 (52)	205 (46)	.401
Diarrhea	136 (27)	14 (22)	122 (28)	.324
Blood test				
<i>Leukocytes</i>				
> 10 000/μL	89 (17)	15 (22)	74 (16)	.223
< 4000/μL	64 (12)	13 (19)	51 (11)	.059
Lymphocytes < 1000/μL	253 (49)	40 (59)	213 (47)	.072
Aspartate aminotransferase > 40 U/L	135 (37)	28 (51)	127 (35)	.026
Alanine aminotransferase > 40 U/L	133 (26)	19 (29)	114 (26)	.535
Lactate dehydrogenase > 250 U/L	317 (63)	45 (68)	272 (62)	.352
D-dimer > 500 μg/L	350 (71)	51 (82)	299 (69)	.039
Creatinine > 1.5 mg/dL	73 (14)	14 (21)	59 (13)	.095
C-reactive protein > 10 mg/L	453 (88)	62 (95)	391 (87)	.057
Chest X-ray				
Abnormal	503 (96)	65 (96)	438 (97)	.726
Local opacity	223 (45)	24 (37)	199 (47)	.168
Diffuse/bilateral opacity	290 (58)	42 (65)	248 (57)	.263
Interstitial pattern	86 (18)	14 (21)	72 (17)	.355
Interstitial-alveolar pattern	193 (39)	22 (34)	171 (40)	.394
ECG				
Sinus rhythm	333/376 (88)	29/43 (67)	304/333 (91)	< .001
Specific treatment for COVID-19	499 (96)	64 (94)	435 (96)	.524
Clinical evolution				
Death	130 (25)	29 (43)	101 (22)	< .001
Respiratory failure	218 (44)	43 (67)	175 (40)	< .001
Mechanical ventilation	39 (9)	5 (9)	34 (9)	.903

COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; SatO₂, arterial oxygen saturation. Values are expressed as No. (%) or mean ± standard deviation.

Furthermore, the prevalence of heart disease was also higher than that recorded in other studies.² These factors may have influenced the high mortality rate recorded in our series.

We draw attention to the lack of awareness regarding the arrhythmogenic potential of the drugs used in COVID-19 and the possibility that SARS-CoV-2 infection, as well as other coronaviruses, could give rise to arrhythmias.³ However, we emphasize that it was only during the first days of the pandemic that the majority of patients did not undergo an ECG. The percentage of patients with ECG rose to 66% in March and 85% in April ($P < .001$) due to the greater involvement of cardiologists during later stages and increased awareness among all staff.

The greatest limitation of this study is that troponin T and brain natriuretic peptide were not measured in most patients, because

this was not stipulated in the protocol. One study found that troponin predicts mortality in patients with COVID-19 and specifically mortality in patients with heart disease.⁴ Furthermore, we could not assess the potential different impact of each heart disease, because the absolute number of the sample was not sufficiently large, nor could we assess the prognostic relevance of ventricular function, because it was not measured in most of the patients.

In summary, cardiovascular risk factors and heart disease are common in patients with COVID-19. Heart disease aggravates the clinical course and worsens life prognosis. The care of patients with COVID-19 has a clear cardiological dimension, thus cardiologists have to be an essential part of multidisciplinary teams in charge of their care.

Table 2

Results of the univariate and multivariate analyses of mortality and the combined event of respiratory failure and death

Variables	Univariate		Multivariate	
	OR (95%CI)	P	OR (95%CI)	P
Mortality				
Age	1.096 (1.074-1.118)	< .001	1.089 (1.062-1.116)	< .001
Hypertension	3.850 (2.480-5.977)	< .001		
Diabetes mellitus	2.578 (1.603-4.144)	< .001		
Chronic kidney disease	3.175 (1.611-6.258)	.001		
Heart disease	2.599 (1.531-4.411)	< .001		
SatO ₂ < 90%	6.172 (3.771-10.099)	< .001	4.998 (2.752-9.078)	< .001
Lymphocytes < 1000/μL	2.388 (1.582-3.604)	< .001		
D-dimer > 500 μg/L	2.305 (1.373-3.869)	.002		
Creatinine > 1.5 mg/dL	9.973 (5.755-17.283)	< .001	7.538 (3.738-15.201)	< .001
C-reactive protein > 10 mg/L	2.728 (1.207-6.166)	.016		
Respiratory failure and death				
Age	1.053 (1.039-1.068)	< .001	1.038 (1.021-1.054)	< .001
Hypertension	3.850 (2.480-5.977)	< .001		
Diabetes mellitus	2.619 (1.637-4.190)	< .001		
Chronic kidney disease	4.044 (1.868-8.755)	< .001		
Heart disease	2.828 (1.646-4.857)	< .001	2.017 (1.050-3.876)	.035
SatO ₂ < 90%	12.362 (6.625-23.068)	< .001	9.109 (4.703-17.644)	< .001
Lymphocytes < 1000/μL	2.554 (1.791-3.641)	< .001		
D-dimer > 500 μg/L	2.092 (1.392-3.144)	< .001		
Creatinine > 1.5 mg/dL	4.796 (2.700-8.520)	< .001	2.874 (1.415-5.836)	.003
C-reactive protein > 10 mg/L	3.810 (1.972-7.364)	< .001	4.309 (1.704-10.892)	.002

95%CI, 95% confidence interval; OR, odds ratio; SatO₂, arterial oxygen saturation.

J. Alberto San Román,^{a,b,*} Aitor Uribarri,^{a,b}
 Ignacio J. Amat-Santos,^{a,b} Álvaro Aparisi,^a Pablo Catalá,^a
 and José Ramón González-Juanatey^{b,c}

^aServicio de Cardiología, Hospital Clínico Universitario, Valladolid, Spain

^bCentro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Spain

^cServicio de Cardiología, Hospital Clínico Universitario, Santiago de Compostela, A Coruña, Spain

*Corresponding author:

E-mail address: asanroman@secardiologia.es (J.A. San Román).

Available online 19 June 2020

REFERENCES

1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323:1061–1069.
2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395:1054–1062.
3. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. *J Cardiovasc Electrophysiol*. 2020;31: 1003–1008.
4. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020. <http://dx.doi.org/10.1001/jamacardio.2020.1017>.

<https://doi.org/10.1016/j.rec.2020.05.025>
 1885-5857/

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Clinical course of COVID-19 in pulmonary arterial hypertension patients



Curso clínico de la COVID-19 en pacientes con hipertensión arterial pulmonar

To the Editor,

The coronavirus disease of 2019 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2).¹ Most patients with severe disease develop pneumonia and acute respiratory distress syndrome (ARDS).¹ Patients with previous cardiovascular conditions seem to be at a higher risk for developing severe forms of COVID-19.¹

Pulmonary arterial hypertension (PAH) is a rare disease with a poor long-term prognosis and a particularly high mortality risk during hospitalizations for noncardiovascular conditions.²

By 10 April 2020, 10 out of 350 PAH patients (100% female, 43.3 years [36.0–47.2]) followed up at our center were diagnosed with COVID-19.

All patients had a previous history of PAH (mean pulmonary artery pressure: 51.5 [44–66] mmHg; pulmonary vascular resistance 10.9 [8–18.4] Wood units). Median time from PAH diagnosis to COVID-19 was 3.9 [0.6–11.1] years.

A total of 7 patients (70%) required hospitalization (length of stay 10 [4–16] days), none in the intensive care unit. Five (50%) developed pneumonia, with ARDS features in 2 patients. Five patients (50%) needed oxygen therapy (3 of them were on domiciliary oxygen therapy). Clinical outcome was favorable in all patients (table 1).

We report the clinical characteristics and outcomes of PAH patients with COVID-19. The mortality risk from noncardiovascular processes for PAH patients is particularly high (9.4% for